Ardelyx Inc (ARDX)
Ardelyx, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for unmet medical needs in the United States and international markets. Its approved products include IBSRELA, a minimally absorbed small-molecule therapy for adults with irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor used to help reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was incorporated in 2007 and changed its name from Nteryx, Inc. to Ardelyx, Inc. in June 2008. Ardelyx is headquartered in Waltham, Massachusetts, and its common stock is listed on the NASDAQ exchange under the symbol ARDX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARDX
|
$5.64
|
11.2% Upside
|
Fair
|
$16.30
|
221.2% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-21.5x
|
8.4x
|
2.9x
|
1.257 B
|
1.246 B
|
15.7%
|
89.0%
|
0.6
|
—
|
64.6%
|
